Reven Holdings announces first patient dosed in clinical trial evaluating RJX for high-risk COVID-19
WESTMINSTER -- Reven Holdings, Inc. today announced the first patient has been dosed in the Phase I/II trial of RJX in high-risk COVID-19 patients ( ClinicalTrials.gov Identifier: NCT04708340; ... Read More
Thursday April 29, 2021 0 comments
Flagship Biosciences and Leap Therapeutics announce partnership and approach using RNAscope and Image Analysis for patient enrollment
WESTMINSTER and CAMBRIDGE, Mass. -- Flagship Biosciences , a leader in data-centric pathology and tissue analysis, and Massachusetts-based Leap Therapeutics (Nasdaq: LPTX), a biotechnology... Read More
Wednesday April 14, 2021 0 comments
Maxar delivers spacecraft bus for NASA’s Psyche Mission to explore asteroid
WESTMINSTER -- Maxar Technologies (NYSE:MAXR) (TSX:MAXR) announced the delivery of the Solar Electric Propulsion (SEP) Chassis to NASA’s Jet Propulsion Laboratory (JPL) for the NASA Discovery... Read More
Tuesday March 30, 2021 0 comments
Maxar awarded contract to support GEOINT exploitation for U.S. Army and combatant commands
WESTMINSTER -- Maxar Technologies (NYSE:MAXR) (TSX:MAXR) today announced it was awarded a U.S. Army contract worth as much as $48.3 million for support services in geospatial intelligence (GEOINT).... Read More
Monday March 29, 2021 0 comments
Flagship Biosciences announces new patent
WESTMINSTER -- Flagship Biosciences announced the United States Patent and Trademark Office has issued the company a new patent, No. 10,839,512, entitled “ Method of dot detection within images... Read More
Thursday February 18, 2021 0 comments
Maxar Technologies appoints Heather Wilson to board of directors
WESTMINSTER -- Maxar Technologies (NYSE:MAXR) (TSX:MAXR) today announced the appointment of Dr. Heather Wilson to serve on the company’s board of directors. Wilson will serve as a director... Read More
Tuesday January 19, 2021 0 comments
Cerapedics announces commercial launch of i-FACTOR®+ Matrix in Canada for surgeries
WESTMINSTER -- Cerapedics announced the full commercial availability of i-FACTOR+ MATRIX for surgical implantation in Canada. "We are excited to announce that i-FACTOR+ Matrix is now fully... Read More
Friday November 6, 2020 0 comments
TriSalus Life Sciences lays out therapeutic strategy upon acquisition of first therapeutic candidate
DENVER and CHICAGO -- TriSalus Life Sciences (TriSalus), an emerging immune-oncology company committed to transforming outcomes for patients with solid tumors, announced its therapeutic clinical... Read More
Monday September 28, 2020 0 comments
IN Sponsors
Browse
Entrepreneurial by Nature
